Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine hydrochloride, an anticholinergic/antispasmodic agent.
## Primary Indications
* Short-term symptomatic relief of mild to moderate pain associated with smooth muscle spasms, particularly in gynecological conditions.
## Adult Dosing
* **Mefenamic Acid:** Typically 500 mg every 8 hours. Maximum daily dose is generally 1500 mg.
* **Dicyclomine Hydrochloride:** Typically 20 mg every 8 hours. Maximum daily dose is generally 120 mg.
* Dosing should be guided by patient response and tolerability. Doses may vary based on local guidelines or specific product labeling.
## Pediatric Dosing
* Data for pediatric use is limited. Mefenamic acid has been used in children, but dicyclomine is generally not recommended in infants and young children due to risks of respiratory depression and anticholinergic toxicity. Dosing, if considered, must be highly individualized and supervised by a pediatrician.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid can affect renal function. Dose reduction may be necessary.
* **Hepatic Impairment:** Use with caution. Mefenamic acid is metabolized by the liver.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* Patients with inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
* Gastrointestinal obstruction or ileus.
* Uncontrolled glaucoma.
* Myasthenia gravis.
* Infants less than 6 months of age (for dicyclomine component).
* Severe renal or hepatic impairment.
* History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, constipation, dizziness, dry mouth, blurred vision, drowsiness.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation; renal toxicity; hepatic toxicity; cardiovascular thrombotic events; hypersensitivity reactions; anticholinergic effects (e.g., urinary retention, confusion, tachycardia).
## Key Drug Interactions
* **NSAIDs:** Increased risk of bleeding and renal toxicity when combined with other NSAIDs, aspirin, or anticoagulants (e.g., warfarin).
* **ACE inhibitors, ARBs, Diuretics:** Reduced antihypertensive effect and increased risk of renal impairment.
* **Lithium:** Increased serum lithium levels.
* **SSRIs/SNRIs:** Increased risk of bleeding.
* **Anticholinergic agents:** Additive anticholinergic effects.
## Monitoring
* **GI:** Monitor for signs and symptoms of GI bleeding or ulceration.
* **Renal:** Monitor renal function, especially in patients with pre-existing renal disease or those on concomitant nephrotoxic agents.
* **Hepatic:** Monitor liver function tests if therapy is prolonged or in patients with liver disease.
* **Ophthalmic:** Monitor for signs of increased intraocular pressure, especially in patients with glaucoma.
## Clinical Pearls
* Meftal spas should be used for the shortest duration necessary to control symptoms.
* Administer with food or milk to minimize gastrointestinal upset.
* Caution is advised in the elderly due to increased risk of adverse effects.
* Be aware of the potential for additive anticholinergic effects with other medications.
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
